Cutaneous phaeohyphomycosis caused by *Exophiala xenobiotica*: A case report

Clarissa Mitri Espanhol, Júlia Kanaan Recuero, Danielle Machado Pagan, Amanda Carvalho Ribeiro, Gerson Vettorato, Rodrigo Pereira Duquía, Laura Luzzatto, Maria Lúcia Scroferneker

*Department of Dermatology of the Hospital Santa Casa de Misericórdia de Porto Alegre, Rua Prof. Annes Dias, 285, Porto Alegre, CEP: 90020-090, Brazil*
*Postgraduate Program in Agricultural and Environmental Microbiology, Federal University of Rio Grande do Sul, Rua Sarmento Leite, 500, Sala 325, Porto Alegre, Rio Grande do Sul, CEP: 90050-170, Brazil*
*Faculty of Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Avenida Ipiranga, 2752, CEP: 90610-000, Brazil*
*Department of Microbiology, ICBS, Universidade Federal do Rio Grande do Sul, Rua Sarmento Leite, 500, Sala 325, Porto Alegre, Rio Grande do Sul, CEP: 90050-170, Brazil*

**Keywords:**
Exophiala xenobiotica  
Phaeohyphomycosis  
Immunosuppressed  
Renal transplantation

**A B S T R A C T**

We report a case of phaeohyphomycosis that affected the leg of a 45-year-old Brazilian man, car mechanic and renal transplanted. The direct mycological examination evidenced dematiaceous septated hyphae. The pathogenic fungal species was identified as *Exophiala xenobiotica*. Antifungal activity in vitro revealed terbinafine as the best antifungal. For treatment, it was chosen surgical excision of the entire lesion and used systemic itraconazole. Phaeohyphomycosis caused by *Exophiala xenobiotica* is extremely rare and is closely related to transplant patients.

1. Introduction

Dematiaceous fungi are found in nature and one of their characteristics is the presence of melanin, responsible for the dark pigmentation of their spores and conidia and that seems to behave as a virulence factor. More than a hundred species and sixty genera of these fungi are connected to a broad spectrum of human infections [1]. The main clinical forms of presentation of the infections through these dematiaceous fungi include phaeohyphomycoses (cutaneous, subcutaneous and systemic), that affect both immunocompetent and immunocompromised individuals [2].

Phaeohyphomycosis is a term used to denominate opportunistic, cutaneous and systemic infections [3]. The mainly genus are *Wangiella*, *Alternaria* and *Exophiala*. There are more than 100 species of fungi associated with phaeohyphomycosis [4]. The most prevalent species are *E. jeaneselmei* and *E. dermatitidis*. *Exophiala xenobiotica* is a rare species. This disease usually affects rural and tropical populations in Central and South America [5,6]. The clinical polymorphism presents in phaeohyphomycosis is exacerbated by iatrogenic immunosuppression, making the diagnosis extremely difficult. The treatment is not defined, and it is usually carried out empirically [7].

2. Case

A 45-year-old white man, resident in Porto Alegre, car mechanic, hypertensive, with hepatitis C and renal transplanted two years ago, using mycophenolic acid, tacrolimus, prednisone, sulfamethoxazole-trimethoprim, sofosbuvir, daclatasvir and anti-hypertensive drugs, was attended in the department of Dermatology of the Hospital Santa Casa de Porto Alegre. He referred pruritic and fibrotic nodule on the right leg three months ago, with no secretion (Fig. 1A and B).

An incisional biopsy was performed, in the first day that he consulted (day 0), with histopathologic features of leveduriform cells and infiltrate which was compatible with phaeohyphomycosis (Fig. 2A and B).

On the same day of the biopsy (day 0), direct and culture microscopic examinations were performed. The fungal isolate was grown in Sabouraud agar medium in 30 °C for 14 days. Mycelium was taken and the genomic DNA was extracted (day14) using Power Soil DNA isolation kit (Mobio, USA). Polymerase chain reaction was performed (day 14) targeting the ITS1-5.8S rDNA-ITS2 region using the ITS1 and ITS4 universal primers and the polymerase chain reaction (PCR) was performed under the following conditions: denaturation step at 94 °C for 5
in vitro antifungal activity MIC were: amphotericin B (16 μg/mL), itraconazole (16 μg/mL), ketoconazole (1 μg/mL), voriconazole (2 μg/mL), posaconazole (0.125 μg/mL) and terbinafine (> 0.5 μg/mL).

The patient returned 30 days after the biopsy with the renal transplant medical team that decided to treat the patient with itraconazole (day 30), that is available in the public health system. Itraconazol was given at a dose of 100 mg every 12 hours for three months (day 120). The patient could not do the treatment with terbinafine because it is not available in the public health system and he was not able to pay for medication. The dermatology team also chose to do a surgical excision of the entire lesion (day 33). The patient is in follow-up with no signs of relapse.

3. Discussion

We report a case of cutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a renal transplant patient treated with systemic itraconazole and surgery. Phaeohyphomycosis is an opportunistic disease. The incidence of phaeohyphomycosis in transplanted patients is increasing in the last decades due to the increased number of transplanted patients and the use of immunosuppressants, the majority of cases occur two years after transplant. Calcineurin inhibitors appear to further increase susceptibility to fungal infections when compared to other immunosuppressants [5,12].

Surgical excision is the first choice for localized and well delimited lesions, it is preferred to use antifungal drugs before and after surgery, but there is no consensus about which drug to choose or how long the treatment will last. It is also recommended in severe or disseminated cases to reduce the doses of immunosuppressants [13–16]. Most melanized fungi are susceptible to azoles, which makes itraconazole and voriconazole the main drugs used, followed by amphotericin B [17].

The early clinical suspicion of phaeohyphomycosis in transplant patients is extremely important, because immunosuppression is the main risk factor for infection and responsible for the systemic spread of the disease, culminating in severe and fatal conditions. In transplant patients, the therapeutic is challenging due to the antifungals high doses required, besides the possibility of drug interactions. Based on our case and in the literature, it is extremely important to use the molecular identification to discover the causative agent, as well as the evaluation of in vitro antifungal activity to use the best treatment for the patient [18].

Declaration of competing interest

There are none.

References

[1] S.G. Revankar, Dematiaceous fungi, Mycoses 50 (2007) 91–101.
[2] H. Nishikawa, Y. Taniguchi, Phaeohyphomycosis due to Exophiala oligosperma in an immunocompromised host, J. Rheumatol. 46 (2019) 6.
[3] S.R. Jinkala, D. Basu, S. Neelaiah, N. Stephen, S.B. Hansman, R. Singh,
Subcutaneous phaeohyphomycosis: a clinical mimic of skin and soft tissue neo-
plasms—a descriptive study from India, World J. Surg. 42 (2018) 3861–3866.

[4] F. Silveira, M. Nucci, Emergence of Black moulds in fungal disease: epidemiology and therapy, Curr. Opin. Infect. Dis. 14 (6) (2001) 679–684.

[5] W.A.P. Oliveira, M.F.L. Borsato, C. Festa Neto, L.A. Rocha, R.S. Nunes, Feo-hifomicoese em transplante renal: relato de dois casos, An. Bras. Dermatol. 91 (1) (2016) 93–96.

[6] A.L. Rossetto, R.A. Pêrio, R.C.B. Cruz, G. Dellatorre, J.C.M. Romeiro, Faeo-hifomicose subcutanea por Exophialaeanselmei localizada na bolsa escrotal - Relato de caso, An. Bras. Dermatol. 85 (4) (2010) 517–520.

[7] A. Singal, D. Pandhi, S.N. Bhattacharya, S. Das, S. Aggarwal, K. Mishra, Pheo-hyphomycosis caused by Exophiala spinifera: a rare occurrence, Int. J. Dermatol. 47 (2008) 44–47.

[8] D. Heidrich, G.M. González, D.M. Pagani, M. Ramírez-Castrillón, M.L. Scroferneker, Chromoblastomicosis caused by Rhinoschidiella similia: case report, Med. Mycol. Case Rep. 16 (2017) 25–27.

[9] R. Staden, The staden sequence analysis package, Mol. Biotechnol. 5 (1996) 233–241.

[10] S.F. Ahlchul, W. Giab, W. Miller, E.W. Myers, D.J. Lipman, Basic local alignment search tool, J. Mol. Biol. 215 (1990) 403–410.

[11] CLSI, Reference method for broth dilution antifungal susceptibility testing of yeasts, Clinical and Laboratory Standards Institute (CLSI), Approved Standard M27-A3, third ed., 2008 Wayne, PA.